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5/6 nephrectomy
End-organ damage
Aims: There is evidence that in addition to hypertension and hyperactivity of the renin–angiotensin system
(RAS), enhanced intrarenal activity of endothelin (ET) system contributes to the pathophysiology and progression
of chronic kidney disease (CKD). This prompted us to examine if this progression would be alleviated by addition
of type A ET receptor (ETA) blockade to the standard blockade of RAS.
Main methods: Ren-2 transgenic rats (TGR) after 5/6 renal ablation (5/6 NX) served as a model of CKD. For RAS
inhibition a combination of angiotensin-converting enzyme inhibitor (trandolapril, 6 mg/L drinking water) and
angiotensin II type 1 receptor blocker (losartan, 100 mg/L drinking water) was used. Alternatively, ETA receptor
blocker (atrasentan, 5 mg·kg−1·day−1 in drinking water) was added to the combined RAS blockade. The
follow-up period was 44 weeks after 5/6 NX, and the rats' survival rate, systolic blood pressure (SBP), proteinuria
and indices of renal glomerular damage were evaluated.
Key ﬁndings: The survival rate was at ﬁrst improved, by either therapeutic regime, however, the efﬁciency of RAS
blockade alone considerably decreased 36 weeks after 5/6 NX: ﬁnal survival rate of 65% was signiﬁcantly lower
than 91% achieved with combined RAS and ETA receptor blockade. SBP was not affected by the addition of ETA
blockade while proteinuria and renal glomerular damage were further reduced.
Signiﬁcance: Our data show that a combined RAS and ETA receptor blockade exhibits additional beneﬁcial effects
on survival rate and the progression of CKD in 5/6 NX TGR, as compared with RAS inhibition alone.© 2013 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Chronic kidney disease (CKD) is a growingmedical problemof current
nephrology, affecting millions of people worldwide (U.S. Renal Data
System: USEDS, 2012). The natural course of progression of CKD toward
end-stage renal disease (ESRD) is independent of the initial insult, and
also the mechanisms underlying the progression of CKD to ESRD are the
same (Brenner, 1985; Zoja et al., 2006; Hostetter, 2003). After diabetes
mellitus, systemic hypertension is the second most common modiﬁable
risk factor for the progression of CKD (Upadhyay et al., 2011; Wheeler
and Becker, 2013; Mancia et al., 2007), and antihypertensive treatment
is crucial among strategies used to slowdown this progression i.e. provide420 241062488.
.
. This is an open access article under“renoprotection” (Ptinopolou et al., 2013; Turner et al., 2012). In addition,
inappropriately activated renin–angiotensin system (RAS) has a critical
role in the progression of CKD to ESRD, and thus antihypertensive RAS
blocking agents, such as angiotensin converting enzyme (ACE) inhibitors
(ACEi) and angiotensin II (ANG II) receptor blockers (ARB), exhibit very
pronounced renoprotective action (Ptinopolou et al., 2013; Turner et al.,
2012; Rüster and Wolf, 2006; Macconi, 2010).
However, the effectiveness of renoprotective action of RAS inhibition
is limited, especially in advanced CKD and therefore more complex
pharmacologic strategies targeting also control systems other than
RAS are needed (Perico et al., 1994; Gordon and Kopp, 2011). This is
supported by ﬁndings that vasoconstrictor endothelin-1 (ET-1) activat-
ing type A ET receptors (ETA) contribute to the pathophysiology of cer-
tain forms of hypertension (Kohan et al., 2011; Vaněčková et al., 2005;
Kang et al., 2009; Sasser et al., 2002). Interestingly, it has been shownthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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contributes to the development of end-organ damage (Rossi et al.,
1999; Cao et al., 2000; Vernerová et al., 2009; Kohan, 2010; Briet and
Burns, 2012). In addition, we demonstrated recently that 5/6 renal
mass reduction (5/6 NX), a model of CKD, resulted in a marked activa-
tion of intrarenal RAS and ET systems, and that ETA receptor blockade
alone retarded the progression of CKD and development of ESRD in 5/6
NX Ren-2 transgenic rats (TGR) (Vaněčková et al., 2012), a model of
ANG II-dependent hypertension with endogenous activation of RAS
(Mullins et al., 1990). This prompted us recently to examine whether
the addition of the selective ETA receptor blockade to the standard RAS
blockade will exhibit additional beneﬁcial effects on the progression of
CKD in 5/6 NX TGR (Kohan et al., 2011; Vaněčková et al., 2005; Kang
et al., 2009; Sasser et al., 2002; Rossi et al., 1999; Cao et al., 2000;
Vernerová et al., 2009; Kohan, 2010; Briet and Burns, 2012; Vaněčková
et al., 2012). However, combined RAS and ETA receptor blockade did
not exhibit greater renoprotection as compared with RAS blockade
alone (Vaněčková et al., 2012). In earlier studies, the treatment with
ETA receptor antagonist did not yield consistent results: some groups
reported important renoprotection (Vaněčková et al., 2005; Kang et al.,
2009; Cao et al., 2000; Vernerová et al., 2009; Brochu et al., 1999;
Benigni et al., 1993; Potter et al., 1997)while otherworkers found no sig-
niﬁcant effect of ETA receptor blockade on the course of end-organ dam-
age after 5/6NX (Pollock and Polakowski, 1997). Nevertheless, at the end
of our earlier experiments with TGR rats (20 weeks after 5/6 NX) the
survival rate tended to be higher after combined RAS and ETA receptor
blockade compared with rats after RAS inhibition alone. Moreover, only
the combined treatment did normalize the glomerular volume to control
HanSD levels (Vaněčková et al., 2012). Noteworthy, there is evidence on
strict correlation of glomerular size (reﬂecting growth) and the degree of
glomerulosclerosis, which gave rise to the view that glomerular hyper-
trophy is the crucial process underlying progression of CKD (Yoshida
et al., 1989a). Not surprisingly, renoprotective effects of antihypertensive
therapies are associated with the reduction of glomerular size (Yoshida
et al., 1989b). All these data made us postulate that in the very long-
term perspective the combined RAS and ETA receptor blockade should
exhibit better renoprotection compared with that obtained with RAS
blockade alone. In the present study we tested this hypothesis in 5/6
NX TGR rats.
Materials and methods
The present study was performed in accordance with the guidelines
and practices established at the Institute for Clinical and Experimental
Medicine Animal Care and Use Committee, and are in accordance with
the national law and EU policy (EEC Council Directive 86/609, OJL 358-
1, December 1987). All the animals used in the studywere housed in fa-
cilities accredited by the Czech Association of Laboratory Animal Care.
Animals
Ren-2 transgenic rats (TGR) are a monogenetically deﬁned form of
hypertension, in whichmurine Ren-2 gene was inserted to the genome
of Hannover Sprague Dawley (HanSD) rats. Male heterozygous TGR
[strain name TGR(mRen2)27] and HanSD rats were housed at 25 °C
under a 12 h light/dark cycle and had free access to normal rat
chow, 0.45% NaCl content, and water. All animals used in this study
were bred at the Department for Experimental Medicine, Institute for
Clinical and Experimental Medicine, from stock animals supplied
by Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Therapeutic regimes
A combination of angiotensin converting enzyme inhibitor
trandolapril (Gopten; Abbot, Prague, Czech Republic), 6 mg/L
drinking water and of angiotensin receptor type II blocker losartan(Lozap; Zentiva, Prague, Czech Republic), 100 mg/L drinking
water, was used (Vaněčková et al., 2012; Kujal et al., 2010). ETA
receptor blockade was achieved with atrasentan (Abbott, Illinois,
USA), 5 mg·kg−1·day−1 in drinking water. The dose of atrasentan
was adjusted weekly to actual water intake; such dosage was previous-
ly found to effectively block ETA receptors (Vaněčková et al., 2005;
Vaněčková et al., 2012). The treatment either with RAS alone or with
a combination of RAS and ETA blockade was started at the age of
9 weeks.
Experimental protocols
Series 1: effects of RAS blockade alone and combined RAS and ETA receptor
blockade on survival rate and signs of end-organ damage
Male HanSD rats aged seven weeks and TGR, derived from several
litters, were randomly assigned to experimental groups. In order to
detect inter-group differences in systolic blood pressure (SBP) over
time, SBP was measured by tail-plethysmography, using a tail-cuff
apparatus (MC 4000; Hatteras Instruments Co. and RTBP 1007; Kent
Scientiﬁc Co.) (Kurtz et al., 2005). Three days before the starting mea-
surements, rats were accustomed to the procedure of indirect tail-cuff
SBP measurements. Measurements of SBP were started 14 days before
5/6 NX and performed at three-day intervals until the end of the exper-
iment. On day 0 (age 9 weeks), 5/6NXwas performed under anesthesia
(tiletamine + zolazepam, Virbac SA, Carros Cedex, France, 8 mg/kg;
and xylasine, Spofa, Czech Republic, 4 mg/kg intramuscularly), as
described previously (Vaněčková et al., 2012; Kujal et al., 2010). After
24 hours' recovery, either appropriate treatment was initiated or rats
were left with no treatment. The following experimental groups were
investigated:
1. Sham-operated HanSD + water (initial n = 9)
2. Sham-operated TGR + water (initial n = 12)
3. 5/6 NX TGR + water (initial n = 22)
4. 5/6 NX TGR + RAS blockade (initial n = 20)
5. 5/6 NX TGR + RAS blockade + ETA blockade (initial n = 22).
The follow-up period was 44 weeks. At weeks 4, 8, 20, 30 and 40
after day 0, after appropriate habituation training, the animals were
placed in individual metabolic cages and their 24-hour urine was col-
lected for the determination of protein. This approach was previously
validated and is regularly used in our studies (Vaněčková et al., 2012;
Kujal et al., 2010). At the end of experiments, rats were decapitated
(without anesthesia), and plasma and tissue ANG II levels were mea-
sured by radioimmunoassay. This approach was used because we have
demonstrated recently that themeasured ANG II levels are altered by an-
esthesia (Vaněčková et al., 2012; Kujal et al., 2010; Huskova et al., 2006;
Červenka et al., 2008; Husková et al., 2010; Honetschlagerová et al.,
2013; Vaňourková et al., 2010). Tissue concentration of endothelin-1
(ET-1) in kidney cortex was measured as described in our previous
studies (Vaněčková et al., 2005; Vaňourková et al., 2010).
The second half of kidney samples was used to assess renal glomer-
ular damage. The kidneys were ﬁxed in 4% formaldehyde, dehydrated
and embedded in parafﬁn. The sections stained with hematoxylin–
eosin and PAS (periodic acid, for Schiff reaction) were examined and
evaluated in a blind-test fashion. Fifty glomeruli in each kidney were
examined on a semi-quantitative scale as described previously (Saito
et al., 1987): grade 0, all glomeruli normal; grade 1, sclerotic area up to
25% (minimal sclerosis); grade 2, sclerotic area 25 to 50% (moderate
sclerosis); grade 3, sclerotic area 50 to 75% (moderate-to-severe
sclerosis); and grade 4, sclerotic area 75 to 100% (severe sclerosis).
The glomerulosclerosis index (GSI) was calculated using the following
formula: GSI = [(1 × n1) + (2 × n2) + (3 × n3) + (4 × n4)]/ (n0 +
n1 + n2 + n3 + n4), where nx is the number of glomeruli in each
grade of glomerulosclerosis.
Renal cortical tubulointerstitial injury was evaluated for inﬂamma-
tory cell inﬁltration, tubular atrophy, and interstitial ﬁbrosis, using
Fig. 1. Survival rates (A) and systolic blood pressure (B) values in sham-operatedHannover
Sprague–Dawley (HanSD, transgene-negative) rats and in heterozygous Ren-2 transgenic
rats (TGR), and in 5/6 nephrectomized (5/6 NX) TGR rats, untreated (water) or receiving,
within a combined RAS blockade, an angiotensin converting enzyme inhibitor (trandolapril,
6 mg/L drinking water) and an angiotensin II receptor blocker (lozap, 100 mg/L drinking
water). Alternatively, the above two-drug RAS blockade was combined with the blockade
of endothelin type A receptors (ETA), using atrasentan (5 mg·kg−1·day−1). *Signiﬁcant
at p b 0.05 compared with baseline values. #p b 0.05 compared with sham-operated TGR
at the same time point. @p b 0.05 compared with other groups at the same time point.
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no atrophy; 1, mild (b25% of the tubuli atrophic); 2, moderate
(25–50% of the tubuli atrophic); and 3, severe (N50% tubuli atro-
phic). Inﬂammatory inﬁltrate and interstitial ﬁbrosis were graded
as mild (grade 1), moderate (grade 2) and severe (grade 3). The lesions
were assessed in at least 30 random and non-overlapping ﬁelds in the
renal cortex.
Morphometric evaluation of the glomerular volumewasmade in the
same kidney sections that were examined for morphological changes,
using the method validated by Lane et al. (1992) and employed in our
recent studies (Vaněčková et al., 2012; Kujal et al., 2010; Čertíková
Chábová et al., 2010), using Nikon NIS-Elements AR 3.1 morphometric
program (Nikon, Tokyo, Japan).
Based on our previous experience (Vaněčková et al., 2012;
Kujal et al., 2010; Husková et al., 2010; Čertíková Chábová et al.,
2010), the ratio of left ventricle weight (LVW) to tibial length
(TL), LVW/TL, was employed to evaluate the degree of cardiac
hypertrophy.Series 2: determinations of ANG II and ET-1 concentrations in conscious
animals in the early phase after 5/6 NX
Animals in this series were divided into analogous experimental
groups and were exposed to the same protocols as in series 1. The aim
of this series was to evaluate the degree of activation of RAS and ET
systems in the early phase of development of CKD after renal mass
reduction and to assess the effects of therapeutic regimes on the activity
of these systems. Fourweeks after either 5/6 NX or sham-operation, rats
from each experimental group (n = 8) were decapitated and ANG II
and ET-1 concentrations were measured as in series 1.
Statistical analysis
Statistical analysis of the datawas performedusingGraph-Pad Prism
software (Graph Pad Software, San Diego, California, USA). ANOVA for
repeated measurements, followed by Student–Newman–Keuls test,
was performed for analysis of BP changes within the groups. Statistical
comparison of other results was made by Student's t-test or one-way
ANOVA. Unless noted, values are expressed as mean ± S.E.M. and
n represents the number of animals. A p-value less than 0.05 was
considered statistically signiﬁcant.
Results
All the sham-operated HanSD rats survived until the end of experi-
ment and sham-operated TGR exhibited 92% survival rate (one TGR un-
expectedly died during the experiment). As shown in Fig. 1A, untreated
5/6 NX TGR began to die at weeks 9–10 after 5/6 NX, and byweek 26 no
animal survived. Both therapeutic regimes dramatically improved the
survival rate, however the efﬁciency of RAS blockade alone considerably
decreased beginning from 36 weeks after 5/6 NX, the ﬁnal survival rate
being 65%. In contrast, the combined RAS and ETA receptor blockade
remained effective and theﬁnal survival ratewas 91%,whichwas signif-
icantly higher compared with RAS inhibition alone.
Sham-operated HanSD rats remained normotensive and sham-
operated TGR were markedly hypertensive, without any signiﬁcant
alterations in SBP throughout the experiment (Fig. 1B). Starting from
the initial SBP of 185 ± 5 mm Hg, 5/6 NX caused a further substantial
increase in SBP, which reached the maximum at week 8 after 5/6 NX
(236 ± 6 mm Hg, p b 0.05). Both RAS inhibition alone and the com-
bined RAS and ETA receptor blockade not only prevented an increase
in SBP in TGR after 5/6 NX, but also reduced SBP levels below those ob-
served in sham-operatedHanSD rats (112 ± 5 and 116 ± 4 mm Hgvs.
135 ± 4 mm Hg, p b 0.05).
As shown in Fig. 2A, sham-operatedHanSD rats showedminimal pro-
teinuria throughout the experiment (at the end: 5.8 ± 1.2 mg/24 h).
Sham-operated TGR exhibited pronounced proteinuria, more than
4-fold higher than that observed in sham-operated HanSD rats,
throughout the experiment. Untreated 5/6 NX TGR revealed a dra-
matic increase in proteinuria reaching the maximum 8 weeks after
5/6 NX (184 ± 16 mg/24 h, p b 0.05 vs. all other corresponding
values). RAS inhibition when applied alone prevented the increase
in proteinuria that occurred after 5/6 NX in TGR, and till the week
20 after 5/6 NX the proteinuria was lower than in sham-operated
TGR. However, after week 30 following 5/6 NX, proteinuria began
to rise and at the end of experiment it was signiﬁcantly higher
than in sham-operated TGR (39.8 ± 3.6 vs. 25.9 ± 2.1 mg/24 h,
p b 0.05). Remarkably, the combined RAS and ETA receptor blockade
not only prevented the increases in proteinuria after 5/6 NX, but also
reduced it below values observed in sham-operated TGR over the whole
duration of experiment; until 30 weeks after 5/6 NX these levels were
similar as observed in sham-operated HanSD rats.
Sham-operated HanSD rats showed a minimal degree of
glomerulosclerosis and kidney tubulointerstitial injury (Figs. 2B
and C) at the end of the study. These parameters were signiﬁcantly
increased in sham-operated TGR. 5/6 NX TGR under RAS blockade
Fig. 2. Proteinuria (A), kidney tubulointerstitial injury (B), glomerulosclerosis index (C), and glomerular volume (D) in sham-operated Hannover Sprague–Dawley (HanSD, transgene-
negative) rats and in heterozygous Ren-2 transgenic rats (TGR), and in 5/6 nephrectomized (5/6 NX) TGR rats, untreated (water) or receiving a combination of angiotensin-converting
inhibitor and angiotensin II receptor blocker (RAS blockade), or subjected to a combination of RAS blockade and endothelin type A receptor (ETA) antagonist (RAS blockade + ETA blockade).
*p b 0.05 compared with the corresponding unmarked values. #p b 0.05 compared with * marked values. @p b 0.05 compared with the corresponding values in all the other groups.
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injury compared with sham-operated HanSD rats and sham-operated
TGR. In contrast, combined RAS and ETA receptor blockade reduced
GSI and kidney tubulointerstitial injury in 5/6NXTGR to levels observed
in sham-operated TGR. As shown in Fig. 2D, there was no signiﬁcant
difference between the glomerular volume in sham-operated HanSD
rats and sham-operated TGR. 5/6 NX TGR under RAS blockade
alone showed marked increases in the glomerular volume compared
with sham-operated TGR (2.84 ± 0.09 vs. 1.49 ± 0.08 × 106 μm3,
p b 0.05). The combined RAS and ETA receptor blockade signiﬁcantly
reduced the glomerular volume in 5/6 NX TGR. Representative ﬁgures
of renal parenchyma are presented in Fig. 3 (A to D).
Sham-operated TGR clearly showed cardiac hypertrophy (evaluated
as the LVW/TL ratio) (Fig. 4), both in the early and in the late phase (four
and 44 weeks, respectively after either sham-operation or 5/6 NX)
when compared with sham-operated HanSD rats 23.96 ± 0.45 vs.
16.72 ± 0.36 and 24.1 ± 0.59 vs. 17.1 ± 0.41, p b 0.05 in both cases).
Already after 4 weeks 5/6 NX induced a marked increase in LVW/TL as
compared with sham-operated TGR (27.22 ± 0.56 vs. 23.96 ± 0.45,
p b 0.05). The two-drug RAS inhibition alone as well as the combined
RAS and ETA receptor blockade prevented the increases not only in the
LVW ratio in 5/6 NX TGR but also in the early phase almost normalized
and in the late phase restored the ratio to levels observed in sham-
operated HanSD rats.PlasmaANG II levels in sham-operated TGRwere signiﬁcantly higher
than that in sham-operated HanSD, and in the early phase 5/6 NX
caused a further increase to levels that were much higher compared
with those in sham-operated TGR (68 ± 5 vs. 21 ± 3 fmol/mL,
p b 0.05) (Fig. 5A). Both RAS inhibition alone and the combined RAS
andETA receptor blockadeprevented the increases in plasmaANG II levels
in 5/6 NX TGR. As shown in Fig. 5B, in the early phase after NX the total
kidney ANG II concentrations exhibited a pattern of changes similar as
that for plasma ANG II levels, but both treatment protocols were even
able to lower kidney ANG II in 5/6 NX TGR to levels observed in sham-
operated HanSD rats. As shown in Fig. 5C, in the late post-NX phase
plasma ANG II levels in sham-operated TGR were still distinctly higher
than that in sham-operated HanSD rats (25 ± 3 vs. 12 ± 3 fmol/mL,
p b 0.05); in 5/6 NX TGR they were not affected by RAS inhibition alone
or combined RAS and ETA receptor blockade. As shown in Fig. 4D, in late
post-NX phase kidney ANG II was about 3-fold higher in sham-operated
TGR than that in sham-operatedHanSD rats. RAS inhibition alone reduced
ANG II concentrations in 5/6NXTGR to values observed in sham-operated
HanSD rats. Remarkably, the combined RAS and ETA receptor blockade
in 5/6 NX TGR decreased intrarenal ANG II concentrations below values
observed in sham-operated HanSD rats (19 ± 3 vs. 51 ± 6 fmol/g,
p b 0.05).
As shown in Fig. 6A, there were no signiﬁcant differences in ET-1
concentrations in kidney cortex between sham-operated HanSD rats
Fig. 3. Representative renal parenchyma. Sham-operated Hannover Sprague–Dawley (HanSD, transgene-negative) rats with normal renal cortex (A).Mild changes in heterozygous Ren-2
transgenic rats (TGR), one glomeruluswith focal segmental glomerulosclerosis (asterisk) (B). 5/6 nephrectomized (5/6NX) TGR rats treatedwith a combination of angiotensin-converting
inhibitor and angiotensin II receptor blocker (RAS blockade) with pronounced glomerular sclerosis and severe diffuse tubulointestitial changes (C). Improved renal parenchyma in 5/6
nephrectomized (5/6 NX) TGR rats treated with a combination of RAS blockade and endothelin receptors type A (ETA) antagonist (RAS blockade + ETA blockade) (D). (PAS 100×).
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resulted, in the early phase, in enormous (about 45-fold) rise in ET-1
levels in kidney cortex. Both RAS inhibition alone and combined
RAS and ETA receptor blockade signiﬁcantly and similarly attenuated
increases in ET-1 concentrations in 5/6 NX TGR. As shown in Fig. 6B,
there were no signiﬁcant differences in ET-1 concentrations in kidney
cortex among experimental groups in the late phase of the experiment.
Discussion
This study compared the effectiveness of two antihypertensive
therapeutic regimes in TGR rats, a unique monogenetic model of RAS-
dependent hypertension, with a particular interest for the effects of
these regimes on the progression of CKD induced by 5/6 NX. The ﬁrst
and most important ﬁnding is that in the very long-term perspective,
addition of ETA receptor blockade to the standard anti-RAS treatment,
i.e. combined RAS and endothelin system inhibition brought additional
beneﬁcial effects compared with those obtained with RAS inhibition
alone. The study is unique in that the follow-up period after 5/6 NX
was about three times longer than 12–20 weeks usually employed
(Zoja et al., 2006; Cao et al., 2000; Vaněčková et al., 2012; Brochu
et al., 1999; Benigni et al., 1993; Potter et al., 1997; Pollock and
Polakowski, 1997; Kujal et al., 2010; Fujihara et al., 2005), the feature
whichmade it possible to come up to the above conclusion. In this con-
text, it is important to note that in our previous study in 5/6 NXwe have
demonstrated that short-term (20 weeks) ETA blockade alone was not
effective in improving renoprotection in TGR rats as compared to RAS
blockade alone and moreover, no beneﬁcial effects were demonstrated
if ETA blockade was added to RAS blockade (Vaněčková et al., 2012).
Since we were interested in the additional effects of ETA blockade
administered concomitantly with RAS blockade, this particular
group was not included in the current study. Moreover, our ﬁnding ofenormous elevation of renal cortical ET-1 levels in the early phase
after 5/6 NX is in accordance with earlier evidence that inappropriately
activated ET system plays an important role in the pathophysiology of
end-organ damage, and indicates an important role of ET system in
the rate of progression of CKD to ESRD (Cao et al., 2000; Vernerová
et al., 2009; Kohan, 2010; Briet and Burns, 2012; Benigni et al., 1993;
Potter et al., 1997).
The second major ﬁnding of the present study is that in TGR the
antihypertensive regime consisting of RAS inhibition alone markedly
improved survival rate, normalized BP and cardiac hypertrophy, and
lowered proteinuria until 36 weeks after 5/6 NX. Thereafter, BP clearly
remained within normotensive range whereas the renoprotective
effects became less evident: reduced survival rate, increased protein-
uria, pronounced renal glomerular and cortical tubulointerstitial injury
and augmented glomerular volume were detected. Not surprisingly,
cardiac hypertrophy was reduced to a similar extent by both treatment
regimens, as similar BP lowering effect was achieved by both treat-
ments. This is in linewith the evidence that left ventricular hypertrophy
correlates well with the degree of hypertension and its reduction is
therefore an important goal in the treatment of CKD patients. These
ﬁndings indicate that efﬁciency of renoprotective effect of RAS blockade
alone is not extended to the late stage of CKD, and further underscore
the need for a search for new pharmacologic renoprotective strategies
targeting systems other than RAS (Turner et al., 2012; Macconi, 2010;
Perico et al., 1994; Gordon and Kopp, 2011).
The reasons for the failure of renoprotective actions of RAS inhibition
alone in the advanced phase of CKD in 5/6NX TGR are not clear. Our cur-
rent data from untreated 5/6 NX TGR are consistent with the accepted
view, that hypertension and increased intrarenal RAS activity are two
critical determinants of the rate of progression of CKD and if they are
controlled, renoprotection would be expected to be sustained (Zoja
et al., 2006; Ptinopolou et al., 2013; Turner et al., 2012; Gordon and
Fig. 4. Cardiac hypertrophy in the early phase [i.e. 4 weeks after 5/6 nephrectomy (5/6 NX)] (A) and late phase (i.e. 44 weeks after 5/6 NX) (B) in sham-operated Hannover Sprague–
Dawley (HanSD, transgene-negative) rats and in heterozygous Ren-2 transgenic rats (TGR), and in 5/6 NX TGR rats, untreated (water) or receiving a combination of angiotensin-
converting inhibitor andangiotensin II receptor blocker (RASblockade), or combination of the RAS blockade and endothelin typeA receptor (ETA) antagonist (RASblockade + ETAblockade).
*p b 0.05 compared with unmarked values. #p b 0.05 compared with all groups.
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worthwhile to emphasize that in our 5/6 NX TGR subjected to RAS inhi-
bition alone, BP was controlled throughout the whole study and it was
even lower than that observed in sham-operatedHanSD rats. Moreover,
kidney ANG II concentrations, a recognized index of intrarenal RAS
activity (Husková et al., 2010; Kobori et al., 2007), were reduced to
levels observed in sham-operated HanSD rats. Thus, since both major
factors responsible for the progression of CKD to ESRD (i.e. hypertension
and intrarenal RAS activity) were under control, other causes must
be sought to explain the failure of renoprotection in the late phase
of CKD. The observation that RAS inhibition alone substantially lowered
ET-1 concentrations in 5/6 NX TGR may here be relevant. However,
since both RAS inhibition alone and combined RAS and ETA blockade
lowered ET-1 concentration to the same extent, the lack of renoprotective
actions of RAS inhibition as observed in the late phase post-5/6NX cannot
be ascribed to increased intrarenal ET system activity.
In this context, of special interest are our results showing that 5/6NX
TGR under RAS inhibition exhibited 2-fold higher glomerular volume
than that observed in sham-operated HanSD rats. One must consider
here the evidence on strict positive correlation between glomerular
size and the degree of glomerulosclerosis, a ﬁnding which is the basis
of the so called “hypertrophy” theory which proposes that hypertrophy
is the mechanism underlying the progression of CKD to ESRD (Yoshida
et al., 1989a; Yoshida et al., 1989b). Therefore, it seems reasonable toassume that the lack of prevention of the harmful compensatory
glomerular growth after renal mass reduction is responsible for the
failure of renoprotection by RAS inhibition alone in the late phase
after 5/6 NX in TGR.
What was the mechanism(s) responsible for the additional
renoprotective effects of the combined RAS and ETA receptor blockade
as comparedwith RAS inhibition alone? Since both antihypertensive re-
gimes brought BP to similar levels thatwere even lower than those seen
in HanSD rats, the reason was not better control of hypertension by the
complex therapy. Therefore, BP-independent renoprotective mecha-
nisms must be considered, also in view of recent ﬁndings showing
that activation of ETA receptors and not increased BP per se, mediates
intrarenal inﬂammatory cell inﬁltration and proliferation in ANG II-
infused hypertensive mice (Boesen et al., 2011). Since ET-1 levels in
kidney cortexwere similarly loweredbyboth antihypertensive regimes,
down to values observed in sham-operated HanSD rats, the difference
in the intrarenal ET content cannot be the explanation, either.
Then, the difference in intrarenal RAS activity should be considered
as a reason for better renoprotective actions of the combined RAS and
ETA receptor blockade. Indeed, we found that while RAS inhibition
alone lowered whole kidney ANG II concentrations to values observed
in sham-operated HanSD rats, the combined RAS and ETA receptor
blockade further signiﬁcantly reduced these concentrations. Given
the critical importance of the intrarenal ANG II augmentation in the
Fig. 5. Plasma and kidney angiotensin II (ANG II) levels in the early phase [i.e. 4 weeks after 5/6 nephrectomy (5/6 NX)] (A and B) and late phase (i.e. 44 weeks after 5/6 NX) (C and D) in
sham-operated Hannover Sprague–Dawley (HanSD, transgene-negative) rats and in heterozygous Ren-2 transgenic rats (TGR), and in 5/6 NX TGR rats, untreated (water) or receiving a
combination of angiotensin-converting inhibitor and angiotensin II receptor blocker (RAS blockade), or combination of the RAS blockade and endothelin type A receptor (ETA) antagonist
(RAS blockade + ETA blockade). *p b 0.05 compared with unmarked values. #p b 0.05 compared with all groups.
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tension (Husková et al., 2010; Kobori et al., 2007), we hypothesize
that this further suppression of intrarenal RAS activity was the main
cause for improved renoprotective action of the combined RAS and
ETA receptor blockade. If thiswas the case,whatwas themechanismun-
derlying further suppression of kidney ANG II after addition of ETA re-
ceptor blockade? Previous studies have demonstrated that enhanced
intrarenal ANG II in ANG II-dependent models of hypertension as well
as in the remnant kidney after 5/6 NX is a consequence of increased pro-
duction of ANG II, which occurs mainly through the ACE-dependent
pathway, and the ANG II type 1 (AT1) receptor-mediated uptake of
ANG II from the circulation (Červenka et al., 2008; Husková et al.,
2010; Kobori et al., 2007; Gonzalez-Villalobos et al., 2013). It is unlikely,
that selective ETA receptor blockade could alter the uptake of ANG II
from the circulation. However, considering the well-known intrarenal
interactions of ET and RAS systems at multiple levels (Kohan et al.,
2011; Sasser et al., 2002; Rossi et al., 1999; Briet and Burns, 2012;
Vaňourková et al., 2010; Barton et al., 1997; Yao et al., 2004), it is
conceivable that antihypertensive therapy combining the blockade of
ACEi, AT1 and ETA receptors could elicit further suppression of intrarenal
ANG II synthesis. Mutual interactions of RAS and ET system should be
considered in light of the late effects of ETA blockade on top of RAS
blockade. Whether these beneﬁcial effects could be also achieved ifETA blockade would start later than RAS blockade needs to be clariﬁed
in future experiments.
A second possible explanation is related to our ﬁnding that com-
bined RAS and ETA receptor blockade substantially reduced glomerular
volume in 5/6 NX TGR, almost to levels observed in sham-operated
TGR. In the light of the aforementioned “hypertrophy” theory of the
mechanism responsible for the progression of CKD (Yoshida et al.,
1989a; Yoshida et al., 1989b; Ketteler et al., 1995), it is conceivable
that a reduction of glomerular volume is another critical factor respon-
sible for the improved renoprotection of combined RAS and ETA recep-
tor blockade as compared with RAS inhibition alone. It is noteworthy
that the “hypertrophy” theory assumes a central role for ANG II in the
development of hypertension and kidney damage (Macconi, 2010;
Ketteler et al., 1995).
Conclusion
Taking all these observations into consideration, we suggest that the
mechanism(s) responsible for the additional renoprotective effects
of the combined RAS and ETA receptor blockade compared with RAS
inhibition alone, as demonstrated in 5/6 NX TGR, are related to the
further suppression of intrarenal RAS activity and attenuation of the
compensatory increase in the glomerular volume. Collectively, the
Fig. 6. Endothelin-1 (ET-1) concentrations in kidney cortex in the early phase [4 weeks
after 5/6 NX)] (A) and late phase (44 weeks after 5/6 NX) (B) in sham-operatedHannover
Sprague–Dawley (HanSD, transgene-negative) rats and in heterozygous Ren-2 transgenic
rats (TGR), and in 5/6 NX TGR rats, untreated (water) or receiving a combination
of angiotensin-converting inhibitor and angiotensin II receptor blocker (RAS blockade),
or a combination of RAS blockade and endothelin type A receptor (ETA) antagonist
(RAS blockade + ETA blockade). *p b 0.05 compared with unmarked values. #p b 0.05
compared with all groups.
304 V. Čertíková Chábová et al. / Life Sciences 118 (2014) 297–305results show that in hypertensive TGR subjected to 5/6 NX the anti-
hypertensive regime consisting of the combined RAS and ETA receptor
blockade provides better long term renoprotection compared with
RAS inhibition alone. These ﬁndings should be considered in attempts
to develop new pharmacologic strategies aimed at slowing the
progression of CKD to ESRD.
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